Neurotransmitter targeting in the treatment of depression

Journal of Clinical Psychiatry

Volumn 74, Issue SUPPL. 2, 2013, Pages 19-24

  Blier, Pierre ^a  

^a Clinical Epidemiology Program   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ATOMOXETINE; CITALOPRAM; DOPAMINE; DOXEPIN; ESCITALOPRAM; NEUROTRANSMITTER; NORADRENALIN; PLACEBO; SEROTONIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRAMADOL; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ARTICLE; ATTENTION DEFICIT DISORDER; BEDTIME DOSAGE; CHRONIC PAIN; COGNITIVE DEFECT; COMORBIDITY; DAILY LIFE ACTIVITY; DEPRESSION; DISEASE COURSE; DRUG CHOICE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG TARGETING; EJACULATION DISORDER; FATIGUE; HUMAN; INSOMNIA; LOW DRUG DOSE; MAJOR DEPRESSION; NEUROTRANSMISSION; NONHUMAN; ORGASM DISORDER; PAIN; PRIORITY JOURNAL; RECURRENCE RISK; REMISSION; SEXUAL AROUSAL DISORDER; SEXUAL DYSFUNCTION; SOMNOLENCE; SUICIDE ATTEMPT; TREATMENT RESPONSE;

EID: 84891388909     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.12084su1c.04     Document Type: Article

References (60)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Arlington, VA: American Psychiatric Association; 2013.
2. Israel JA. The impact of residual symptoms in major depression. Pharmaceuticals. 2010;3(8):2426-2440.
3. Kennedy N, Paykel ES. Residual symptoms at remission from depression: impact on long-term outcome. J Affect Disord. 2004;80(2-3):135-144.
4. Kennedy N, Foy K. The impact of residual symptoms on outcome of major depression. Curr Psychiatry Rep. 2005;7(6):441-446.
5. Paykel ES, Ramana R, Cooper Z, et al. Residual symptoms after partial remission: an important outcome in depression. Psychol Med. 1995;25(6):1171- 1180.
6. Nierenberg AA, Husain MM, Trivedi MH, et al. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med. 2010;40(1):41-50.
7. Fava M. Pharmacological approaches to the treatment of residual symptoms. J Psychopharmacol. 2006;20(suppl 3):29-34.
8. Marazziti D, Consoli G, Picchetti M, et al. Cognitive impairment in major depression. Eur J Pharmacol. 2010;626(1):83-86.
9. Chen LS, Eaton WW, Gallo JJ, et al. Empirical examination of current depression categories in a population-based study: symptoms, course, and risk factors. Am J Psychiatry. 2000;157(4):573-580.
10. McClintock SM, Husain MM, Wisniewski SR, et al. Residual symptoms in depressedoutpatients who respond by 50% but do not remit to antidepressant medication. J Clin Psychopharmacol. 2011;31(2):180-186.
11. Hasin DS, Goodwin RD, Stinson FS, et al. Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Arch Gen Psychiatry. 2005;62(10):1097-1106.
12. Egede LE. Major depression in individuals with chronic medical disorders: prevalence, correlates and association with health resource utilization, lost productivity and functional disability. Gen Hosp Psychiatry. 2007;29(5):409-416.
13. Goethe JW, Woolley SB, Cardoni AA, et al. Selective serotonin reuptake inhibitor discontinuation: side effects and other factors that influence medication adherence. J Clin Psychopharmacol. 2007;27(5):451-458.
14. Prabhakar D, Balon R. How do SSRIs cause sexual dysfunction? Curr Psychiatr. 2010;9(12).
15. Bull SA, Hunkeler EM, Lee JY, et al. Discontinuing or switching selective serotoninreuptake inhibitors. Ann Pharmacother. 2002;36(4):578-584.
16. Seo D, Patrick CJ, Kennealy PJ. Role of serotonin and dopamine system interactions in the neurobiology of impulsive aggression and its comorbidity with other clinical disorders. Aggress Violent Behav. 2008;13(5):383-395.
17. Nordstrom P, Samuelsson M, Asberg M, et al. CSF 5-HIAA predicts suicide risk after attempted suicide. Suicide Life Threat Behav. 1994;24(1):1-9.
18. Szabo ST, de Montigny C, Blier P. Progressive attenuation of the firing activity of locus coeruleus noradrenergic neurons by sustained administration of selective serotonin reuptake inhibitors. Int J Neuropsychopharmacol. 2000;3(1):1-11.
19. Kawahara Y, Kawahara H, Kaneko F, et al. Long-term administration of citalopram reduces basal and stress-induced extracellular noradrenaline levels in rat brain. Psychopharmacology (Berl). 2007;194(1):73-81.
20. Dremencov E, El Mansari M, Blier P. Effects of sustained serotonin reuptake inhibition on the firing of dopamine neurons in the rat ventral tegmental area. J Psychiatry Neurosci. 2009;34(3):223-229.
21. Hains AB, Arnsten AFT. Molecular mechanisms of stress-induced prefrontal cortical impairment: implications for mental illness. Learn Mem. 2008;15(8):551-564.
22. Blier P. Rational site-directed pharmacotherapy for major depressive disorder [published online ahead of print June 10, 2013]. Int J Neuropsychopharmacol.
23. Szabo ST, Blier P. Effects of serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibition plus 5-HT2A receptor antagonism on the firing activity of norepinephrine neurons. J Pharmacol Exp Ther. 2002;302(3):983-991.
24. Trivedi MH, Hollander E, Nutt D, et al. Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression. J Clin Psychiatry. 2008;69(2):246-258.
25. Moron JA, Brockington A, Wise RA, et al. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J Neurosci. 2002;22(2):389-395.
26. Linner L, Endersz H, Ohman D, et al. Reboxetine modulates the firing pattern of dopamine cells in the ventral tegmental area and selectively increases dopamine availability in the prefrontal cortex. J Pharmacol Exp Ther. 2001;297(2):540-546.
27. Tanda G, Carboni E, Frau R, et al. Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential? Psychopharmacology (Berl). 1994;115(1-2):285-288.
28. Fawcett J, Barkin RL. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord. 1998;51(3):267-285.
29. Fava M. Symptoms of fatigue and cognitive/executive dysfunction in major depressive disorder before and after antidepressant treatment. J Clin Psychiatry. 2003;64(suppl 14):30-34.
30. Pae CU, Lim HK, Han C, et al. Fatigue as a core symptom in major depressive disorder: overview and the role of bupropion. Expert Rev Neurother. 2007;7(10):1251-1263.
31. Targum SD, Fava M. Fatigue as a residual symptom of depression. Innov Clin Neurosci. 2011;8(10):40-43.
32. Demyttenaere K, De Fruyt J, Stahl SM. The many faces of fatigue in major epressive disorder. Int J Neuropsychopharmacol. 2005;8(1):93-105.
33. Papakostas GI, Nutt DJ, Hallett LA, et al. Resolution of sleepiness and fatigue in major depressive disorder: a comparison of bupropion and the selective serotonin reuptake inhibitors. Biol Psychiatry. 2006;60(12):1350-1355.
34. Marin H, Menza MA. Specific treatment of residual fatigue in depressed patients. Psychiatry (Edgmont). 2004;1(2):12-18.
35. Stahl SM, Zhang L, Damatarca C, et al. Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder. J Clin Psychiatry. 2003;64(suppl 14):6-17.
36. Yamashita H, Mori K, Nagao M, et al. Effects of changing from typical to atypical antipsychotic drugs on subjective sleep quality in patients with schizophrenia in a Japanese population. J Clin Psychiatry. 2004;65(11):1525- 1530.
37. Corrigan MH, Denahan AQ, Wright CE, et al. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety. 2000;11(2): 58-65.
38. Aiken CB. Pramipexole in psychiatry: a systematic review of the literature. J Clin Psychiatry. 2007;68(8):1230-1236.
39. Papakostas GI, Petersen TJ, Burns AM, et al. Adjunctive atomoxetine for residual fatigue in major depressive disorder. J Psychiatr Res. 2006;40(4):370-373.
40. Fava M, Thase ME, DeBattista C, et al. Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness. Ann Clin Psychiatry. 2007;19(3):153-159.
41. Volkow ND, Fowler JS, Logan J, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA. 2009;301(11):1148-1154.
42. Romera I, Perez V, Ciudad A, et al. Residual symptoms and functioning in depression, does the type of residual symptom matter? a post-hoc analysis. BMC Psychiatry. 2013;13:51.
43. Nierenberg AA, Keefe BR, Leslie VC, et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry. 1999;60(4):221-225.
44. Asnis GM, Chakraburtty A, DuBoff EA, et al. Zolpidem for persistent insomnia in SSRI-treated depressed patients. J Clin Psychiatry. 1999;60(10):668-676.
45. Goeldner C, Ballard TM, Knoflach F, et al. Cognitive impairment in major depression and the mGlu2 receptor as a therapeutic target. Neuropharmacology. 2013;64:337-346.
46. Berigan TR. Atomoxetine used adjunctively with selective serotonin reuptake inhibitors to treat depression. Prim Care Companion J Clin Psychiatry. 2004;6(2):93-94.
47. Clayton AH, Montejo AL. Major depressive disorder, antidepressants, and sexual dysfunction. J Clin Psychiatry. 2006;67(suppl 6):33-37.
48. Baldwin DS, Palazzo MC, Masdrakis VG. Reduced treatment-emergent sexual dysfunction as a potential target in the development of new antidepressants. Depress Res Treat. 2013;2013:256841.
49. Labbate LA, Croft HA, Oleshansky MA. Antidepressant-related erectile dysfunction: management via avoidance, switching antidepressants, antidotes, and adaptation. J Clin Psychiatry. 2003;64(suppl 10):11-19.
50. Clayton AH, Warnock JK, Kornstein SG, et al. A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexua dysfunction. J Clin Psychiatry. 2004;65(1):62-67.
51. Nurnberg HG, Hensley PL. Sildenafil citrate for the management of antidepressantassociated erectile dysfunction. J Clin Psychiatry. 2003;64(suppl 10):20-25.
52. Montejo AL, Llorca G, Izquierdo JA, et al; Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. J Clin Psychiatry. 2001;62(suppl 3):10-21.
53. PubMed 53. Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry. 2002;63(4):357-366.
54. Bair MJ, Robinson RL, Katon W, et al. Depression and pain comorbidity: a literature review. Arch Intern Med. 2003;163(20):2433-2445.
55. Trivedi MH. The link between depression and physical symptoms. Prim Care Companion J Clin Psychiatry. 2004;6(suppl 1):12-16.
56. Huang X, Li C, Luo YL, et al. Efficacy of venlafaxine extended-release monotherapy for first-episode depression with painful physical symptoms. Neuroreport. 2013;24(7):364-369.
57. Reeves RR, Burke RS. Tramadol: basic pharmacology and emerging concepts. Drugs Today (Barc). 2008;44(11):827-836.
58. Barber J. Examining the use of tramadol hydrochloride as an antidepressant. Exp Clin Psychopharmacol. 2011;19(2):123-130.
59. Maizels M, McCarberg B. Antidepressants and antiepileptic drugs for chronic non-cancer pain. Am Fam Physician. 2005;71(3):483-490.
60. Stahl SM. Anticonvulsants and the relief of chronic pain: pregabalin and gabapentin as a2d ligands at voltage-gated calcium channels. J Clin Psychiatry. 2004;65(5):596-597.